调节性B细胞
CD19
过继性细胞移植
人口
抑制器
化学
B细胞
髓源性抑制细胞
免疫学
癌症研究
生物
白细胞介素10
T细胞
细胞因子
抗原
癌症
医学
免疫系统
抗体
环境卫生
遗传学
作者
Wenyan Chen,Xiaomin Ning,Yang Liu,Tingting Shen,Mengru Liu,Hui Yin,Yue Ding,Jingwen Zhou,Rui Yin,Liangliang Cai,Yuhan Wu,Qian Li
出处
期刊:Immunology
[Wiley]
日期:2024-02-08
卷期号:172 (1): 127-143
摘要
Abstract Myeloid‐derived suppressor cells (MDSCs) increase in number and gain immunosuppressive functions in tumours and many other pathological conditions. MDSCs are characterized by their strong T‐cell immunosuppressive capacity. The effects that MDSCs may have on B cells, especially within the tumour microenvironment, are less well understood. Here, we report that either monocytic MDSCs or polymorphonuclear MDSCs can promote increases in interleukin (IL)‐10‐expressing CD19 hi FcγRIIb hi regulatory B cells in vitro and in vivo. Splenic transitional‐1, ‐2, and ‐3 cells and marginal zone B cells, but not follicular B cells, differentiate into IL‐10‐expressing CD19 hi FcγRIIb hi regulatory B cells. The adoptive transfer of CD19 hi FcγRIIb hi regulatory B cells via tail vein injection can promote subcutaneous 3LL tumour growth in mice. The expression of programmed death‐ligand 1 on MDSCs was found to be strongly associated with CD19 hi FcγRIIb hi regulatory B cell population expansion. Furthermore, the frequency of circulating CD19 + FcγRII hi regulatory B cells was significantly increased in advanced‐stage lung cancer patients. Our results unveil a critical role of MDSCs in regulatory B‐cell differentiation and population expansion in lung cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI